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Lower lid entropion secondary to treatment with




Introduction: The use of alpha-1a receptor antagonists (tamsulosin) is widely accepted in the treatment of benign
prostatic hypertrophy (BPH). It has previously been implicated as a causative agent in intra-operative floppy iris
syndrome due to its effects on the smooth muscle. We report a case of lower lid entropion that may be related to
a patient commencing treatment of tamsulosin.
Case presentation: A 74-year-old Caucasian man was started on alpha 1-a receptor antagonist (Tamsulosin)
treatment for benign prostatic hypertrophy. Eight days later, he presented to the ophthalmology unit with a right
lower lid entropion which was successfully treated surgically with a Weiss procedure.
Conclusion: We report a case of lower lid entropion that may be secondary to the recent use of an alpha-1a
blocker (tamsulosin). This can be explained by considering the effect of autonomic blockade on alpha-1 receptors
in the Muller’s muscle on a patient that may already have an anatomical predisposition to entropion formation due
to a further reduction in muscle tone.
Introduction
The use of alpha-1a receptor antagonists (tamsulosin) is
widely accepted in the treatment of benign prostatic
hypertrophy (BPH). It has previously been implicated as
a causative agent in the intra-operative floppy iris syn-
drome due to its effects on smooth muscle. We report a
case of lower lid entropion that may be related to a
patient commencing treatment with tamsulosin.
Case presentation
A 74-year-old Caucasian man presented to the
ophthalmology outpatient clinic with a five-day history
of a heavy and sore right eye. His past ocular history
included cataract surgery and left penetrating kerato-
plasty for Fuch’s endothelial dystrophy. He was main-
tained on long term flurometholone eye drops once a
day in his left eye. He also had been prescribed timolol
eye gel (Nyogel) once a day to the left eye for ocular
hypertension. His past medical history included parox-
ysmal atrial fibrillation and hypercholesterolemia.
Other regular medications included oxazepam, clopi-
dogrel, lanzoprazole, flecainide acetate and sildenafil.
Eight days prior to presentation to the eye clinic, our
patient consulted a urologist with complaints of fre-
quency of micturition and had been started on tamsu-
losin (Flomaxtra XL) 0.4 mg once a day with good
response.
On examination, he was found to have visual acuities
of 6/9 with glasses improving to 6/6 with pinhole in
both eyes. A right lower lid entropion was noted with
moderate lid laxity. He subsequently underwent a right
lower lid entropion repair (Weiss procedure) under local
anaesthetic with good results.
Discussion
Tamsulosin is the most commonly prescribed drug for
the treatment of benign prostatic hyperplasia. It acts by
selectively antagonising alpha-1a adrenergic receptors
found in the bladder neck and prostate smooth muscle
resulting in relaxation of the muscles and improvement
of urinary flow. It has the therapeutic advantage of
being uroselective and therefore has fewer cardiovascu-
lar side effects. A daily medication of 0.4 mg of tamsulo-
sin has been found to be safe, well-tolerated and
clinically effective in improving symptoms and urinary
flow rate in patients with symptomatic BPH [1]. * Correspondence: salmanwqr@gmail.com
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receptors in iridial smooth muscle, it has also been
documented to cause the intra-operative floppy iris syn-
drome (IFIS) [2]. It is believed that tamsulosin blocks
the iris dilator muscle and this constant receptor block-
ade results in semi-permanent loss of muscle tone lead-
ing to a flaccid and floppy iris. However, no significant
relationship has been found between the duration of
tamsulosin intake and severity of IFIS [3].
The Muller’s muscle is a smooth muscle that lies just
deep to the orbital septum in both upper and lower eye
lids. Its primary function is to assist in the retraction of
both lids and is primarily innervated by alpha-2 adrener-
gic receptors although recent studies have also shown
t h ep r e s e n c eo fa l p h a - 1r e c e p t o r s[ 4 ] .T h i si so fc l i n i c a l
significance in Horner’s syndrome where the interrup-
tion of sympathetic supply to the muscle can result in
ptosis and an elevation of the lower lid by as much as 1
mm [5]. Although not reported to be of benefit in
entropion management, apraclonidine has shown
improvement in lid function in Horner’s syndrome.
Apraclonidine is a weak alpha-1 agonist and a potent
alpha 2 agonist. In Horner’s syndrome, there is upregu-
lation of alpha 1 receptors leading to denervation hyper-
sensitivity. This, in turn, causes the observed lid
retraction with apraclonidine [6,7]. Building on this
knowledge and given the recent use of tamsulosinin our
patient, we hypothesize that there was an alpha-1 block-
ade on the Muller’s muscle in the right lower lid. This
led to increased lower lid laxity, which may have been
predisposed to the development of the entropion soon
after commencing tamsulosin.
Conclusion
We report a case of lower lid entropion that may be
secondary to the recent use of an alpha-1a blocker (tam-
sulosin). This can be explained by considering the effect
of autonomic blockade on alpha-1 receptors in the Mul-
ler’s muscle on a patient that may already have an ana-
tomical predisposition to entropion formation due to a
further reduction in muscle tone.
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